ABSTRACT
INTRODUCTION
Arenaviruses cause chronic infections of rodents with a worldwide distribution (8) .
Invasion of human dwellings by infected rodents can result in human infections through mucosal exposure to aerosols, or by direct contact of abrade skin with infectious material.
Several arenaviruses cause hemorrhagic fever (HF) disease in humans and pose significant public health concerns in their endemic region (17, 21, 28, 46, 63) Arenaviruses are classified into two main groups, Old (OW) and New (NW) world (8) .
The OW Lassa virus (LASV), causative agent of Lassa fever (LF), is the most significant pathogen among arenaviruses. LASV is estimated to infect several hundred thousand individuals annually in West Africa, which is associated with high morbidity and significant mortality. Likewise, the NW Junin virus (JUNV) is the causative agent of Argentine HF, a disease associated with high mortality (87) . On the other hand, the worldwide-distributed prototypic arenavirus, lymphocytic choriomeningitis virus (LCMV), is considered to be a neglected human pathogen of clinical significance especially in congenital infection (2-4, 25, 51) Moreover, LCMV poses a special thread to immunocompromised individuals, as has been illustrated by fatal cases of LCMV infection associated with organ transplants in humans (18, 64) . Despite the arenavirus significant impact in human health there are no FDA-licensed vaccines, although the live attenuated strain of JUNV, Candid#1, has been licensed in Argentina. However, Candid#1 does not protect against LASV or LCMV infections. Likewise, current antiarenaviral therapies are limited to an off-label use of the nucleoside analogue ribavirin that is only partially effective and can cause significant side effects (12, 53, 61) . Therefore, it is important to develop novel antiviral strategies to combat humanpathogenic arenaviruses, a task that would be facilitated by a detailed understanding of the molecular and cell biology of arenaviruses.
Arenaviruses are enveloped viruses with a bi-segmented, negative-strand RNA genome and a life cycle restricted to the cell cytoplasm. Each genome RNA segment, S and L, uses an ambisense coding strategy to direct the expression of two viral polypeptides in opposite orientation, separated by a non-coding intergenic region. The S segment encodes the viral nucleoprotein (NP) and the glycoprotein precursor, GPC that is processed by the cellular site 1 protease to generate the mature virion surface glycoproteins, GP1 and GP2. Trimers of GP1/GP2 form the spikes that decorate the virus surface and mediate virus cell entry via receptor-mediated endocytosis. α-Dystroglycan (αDG) has been identified as a primary receptor of OW arenaviruses, including LCMV and LASV (9) , whereas human pathogenic Clade B NW arenaviruses, including JUNV, use human transferrin receptor to enter cells (67) . The L segment encodes the viral RNA dependent RNA polymerase, L protein, and the small RING finger protein, Z, which is the counterpart of the matrix protein found in many enveloped negative strand RNA viruses (75, 76) . The identification and characterization of arenavirus-host cell factor interactions required to complete the virus life cycle may uncover novel targets and facilitate the discovery of drugs to combat human-pathogenic arenaviruses. In this regard, a recent genome wide siRNA screen identified a variety of host genes involved in multiplication of both vesicular stomatitis virus (VSV) and LCMV (60). One of the candidates identified was sodium hydrogen exchanger three (NHE3), a molecule implicated in receptor-mediated endocytosis (15, 88) . In this work we have investigated the role of NHEs in LCMV multiplication. We document that EIPA, a potent inhibitor of the NHE activity (45) , as well as of macropinocytosis (15, 88) , exerted a robust inhibitory effect on LCMV multiplication and this effect was due to a blockade of LCMV cell entry, rather than an effect of EIPA on viral RNA replication, gene expression or budding. OW and NW arenaviruses have been shown to follow different endocytic pathways (69) . Thus, endocytic vesicles of the OW arenavirus LCMV are non-coated and LCMV cell entry process was reported to be cholesterol-dependent but clathrin-, dynamin-, caveolin-, ARF6-, flotillin-, and actin-independent (6, 66, 70, 71, 79, 86) . In contrast, the NW arenavirus, JUNV, is internalized via coated vesicles using a clathrinand dynamin-dependent pathway (21, 44, 70, 71) . However, we found that NHE activity was required for efficient cell entry mediated by the GPs of both OW (LASV) and NW (JUNV) HF arenaviruses. Moreover, Pak1 and actin were involved in LCMV entry in human cells, supporting a role of macropinocytosis in this process. Finally, we document that the NHE1 inhibitor zoniporide (22), used in clinical trials for ischemia (19), inhibited LCMV propagation in cultured cells. Our findings suggest that targeting NHEs could represent a novel antiviral strategy to combat human-pathogenic arenaviruses.
Virus titration. LCMV titers were determined using an immunofocus assay as described (5) . Briefly, 10-fold serial virus dilutions were used to infect Vero cell monolayers in a 96-well plate, and at 20 h p.i., cells were fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS). After cell permeabilization by treatment with 0.3% Triton X-100 in PBS containing 3% bovine serum albumin (BSA), cells were stained by using an anti-NP rat monoclonal antibody (VL-4) and an Alexa Fluor 568-labeled anti-rat second antibody. VSV titers were determined by a plaque assay.
Growth kinetics. Cells were infected with rLCMVs for 1 h at the indicated moi. At the indicated times post-infection (p.i.), cell culture supernatants were collected and viral titers determined using an immunofocus assay. In the indicated cases, 20 mM ammonium chloride (NH 4 Cl) was added at 4 h p.i. to prevent secondary infections.
Cytotoxicity assay. The effect of compounds on cell viability was assessed using the (Fig 1A) . Consistent with this finding, growth of wild type (WT) ARM was also inhibited in a dose-dependent manner by EIPA (Fig 1B) . In contrast, and consistent with published observations (55), infection with rVSV-WT was not affected significantly by EIPA treatment (Fig 1B) . EIPA inhibited LCMV multiplication at concentrations that did not affect cell viability (Fig 1C) . These results suggested that NHEs are required for efficient multiplication of LCMV.
Effect of EIPA on LCMV cell entry.
We next asked what step of the LCMV life cycle was blocked by EIPA. To this end, we performed a time of addition experiment where we added EIPA at several times prior and after infection with either r3ARM/GFP or r3Cl-13/GFP and monitored GFP expression at 24 h p.i.. We used both r3ARM/GFP and r3Cl-13/GFP to examine whether high (Cl-13) or low (ARM) viral GP1 affinity for αDG, a bona fide receptor for LASV and most immunosuppressive strains of LCMV (80), could influence NHE-dependent virus cell entry. Addition of EIPA 60 min prior infection strongly inhibited spread of both r3ARM/GFP and r3Cl-13/GFP, whereas addition of EIPA at 60 min, or later, p.i. did not significantly affected virus multiplication (Fig 2A) . Because by 60 min p.i. LCMV cell entry is completed, our finding suggested that EIPA blocked an early step of LCMV cell entry. To further investigate this issue we examined the effect of EIPA on cell entry of a recombinant VSV expressing either its homologous surface on July 9, 2017 by guest http://jvi.asm.org/ glycoprotein G (rVSV-WT), or the GPC from Cl-13 strain of LCMV (rVSV/Cl-13GPC).
Pre-treatment with EIPA inhibited multiplication of rVSV/Cl-13GPC in a dose-dependent manner (Fig 2B) , whereas multiplication of rVSV-WT was hardly affected (20% reduction in titer) by EIPA pre-treatment. These results suggested that EIPA inhibited cell entry mediated by LCMV GP. Production of infectious LCMV progeny can be detected about six to eight hours p.i., and therefore inhibition of a post-entry event could have contributed to a decrease in virus titers at 12 and 24 h p.i. in EIPA treated cells (see Fig   1) . However, the same EIPA inhibitory effect was observed in infected cells when 20 mM NH 4 Cl was added at 4 h p.i. to prevent secondary infections (Fig 2C) . To further confirm a specific effect of EIPA on LCMV cell entry we tested whether EIPA interfered with the activity of a LCMV minigenome (MG), which would reflect an effect on RNA biosynthetic processes, both replication and transcription, directed by the virus polymerase complex, in isolation from other steps of the virus life cycle. EIPA did not affect LCMV MG activity (Fig 2D) . Likewise, we also examined whether EIPA could inhibit Z-mediated budding.
For this, we transfected BHK-21 cells with pCAGGS-LCMV-ZFlag, and 5 h later, cells were washed and cultured in fresh medium. At 24 h posttransfection, the medium was replaced with fresh medium containing EIPA at the indicated concentration, and 24 h later VLP-containing tissue culture supernatants isolated and their levels determined by western blot. EIPA treatment did not affect the efficiency of Z budding (Fig 2E) .
Effect of EIPA on cell entry mediated by HF arenavirus GPs. We next examined whether the inhibitory effect of EIPA on LCMV cell entry could be extended to HF arenaviruses. To this end, we took advantage of rLCMVs expressing GPC from the two most relevant HF arenaviruses, LASV and JUNV, referred to as rARM/LASVGPC and rARM/JUNVGPC, respectively. As control we used an rLCMV that expressed VSV G instead of its own GPC (rARM/VSVG). Consistent with results shown in figure 2B , EIPA on July 9, 2017 by guest http://jvi.asm.org/
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did not inhibited multiplication of rARM/VSVG, whereas EIPA inhibited very robustly multiplication of rARM/LASVGPC in BHK-21 cells (Fig 3A) . Human transferrin receptor was identified as a cellular receptor for NW arenaviruses including JUNV (67), however JUNV can infect and multiply in BHK-21 cells, suggesting that JUNV can enter rodent cells using a transferrin receptor-independent mechanism. Notably, EIPA inhibited also very efficiently multiplication of rARM/JUNVGPC in BHK-21 cells (Fig 3A) . However, EIPA did not inhibit significantly multiplication of rARM/JUNVGPC in A549 human cells expressing human transferrin receptor 1 (Fig 3B) . values with respect to the one obtained for cells transfected with GFP alone that was assigned 100% (Fig 4A,B) . Expression of DN forms of Arf1 and Cdc42 resulted in modest reduction of the numbers of NP + cells (25 and 20% reduction, respectively), while expression of DN GRAF1 did not affect the numbers of NP + cells (Fig 4B) . Similar findings were observed in cells transfected with WT versions of Arf1, Cdc42 or GFAF1
Role of the CLIC/GEEC
(not shown). The Rho-GAP-domain-containing protein GRAF1 plays a critical role in coordinating small G protein signaling and membrane remodeling to enable internalization of CLIC/GEEC pathway cargoes (14, 42) . Therefore our observation that LCMV cell entry was not affected by over-expression of a DN form of GRAF1 indicates that it is highly unlikely that the CLIC/GEEC pathway plays a significant role in cell entry of LCMV. To rule out the possibility that DN forms of Arf1, Cdc42, and GRAF1 might (Fig 4C) . WT and DN forms of Arf1 and Cdc42 were expressed to similar levels (Fig 4C) .
In contrast, DN GRAF1 was expressed at significantly higher levels than its WT version, but both WT and DN forms of GRAF1 exhibited the same very modest effect on CAT expression levels (Fig 4C) . To confirm that under our experimental conditions the DN form of GRAF1 was able to inhibit GRAF1-dependent cell entry of molecules, we examined the effect of WT and DN forms of GRAF1 on AVV2 cell entry, which was shown to be GRAF1-dependent (58 However, our finding that EIPA inhibited LCMV entry in BHK-21 and A549 cells without the contribution of the CLIC/GEEC endocytotic pathway, led us to explore whether macropinocytosis could contribute to arenavirus cell entry in a cell-type specific manner.
To examine this issue we tested the effect of cytochalasin D (CytD), an inhibitor of actin multimerization, on early viral gene expression in r3ARM/CAT-infected A549 and BHK-21 cells (Fig 5A) . In contrast to previous reports, CytD inhibited very strongly viral gene expression, as determined by levels of CAT protein expression, at early time points (8 h) p.i. in both A549 and BHK-21 cells (Fig 5B) . At the lowest (1 µM) concentration used CytD resulted in 85% and 40 % reduction of CAT expression in A549 and BHK-21 cells, respectively, whereas within the range (1-10 µM) of concentrations tested CytD did not affect expression of the house keeping gene GAPDH (Fig 5B) or cell viability (Fig 5D) .
To determine whether this CytD-mediated inhibitory effect on viral gene expression was mainly due to disruption of the virus cell entry step, we compared the effect of CytD on viral gene expression when added prior or after initiation of virus infection. We treated A549 cells with CytD (1 µM) before or after infection with r3ARM/CAT and determined
CAT expression levels at 8 h p.i.. CytD treatment prior, but not 1 h after, addition of virus inoculum resulted in 80% reduction of CAT expression levels (Fig 5C) .
Role of Pak1 in cell entry of LCMV. Since we found that actin remodeling was Cl-13 strains of LCMV (Fig 6A) without affecting cell viability (Fig 6B) . To gain additional insights about the mechanisms by which IPA-3 interfered with LCMV infection, we infected IPA-3-treated (10 µM) cells with rVSV-WT or rVSV/Cl-13GPC. IPA-3 caused about 95 % reduction in production of infectious rVSV/Cl-13GPC, whereas affected production of infectious rVSV-WT by less than 25 % (Fig 6A) . We also examined CAT protein expression levels were significantly reduced (33 %) in cells expressing the DN form of Pak1 compared cells expressing either WT Pak1 or the control β-gal (Fig 6C) .
Both WT and DN Pak1 proteins were expressed to similar levels in transfected cells.
These data suggested that Pak1 is involved in cell entry of LCMV and further supported a contribution of macropinocytosis to cell entry of LCMV. (Fig 7A) without affecting cell viability (Fig 7C) . Likewise, production of rVSV/Cl-13GPC, but not rVSV-WT, was significantly inhibited by EIPA treatment (Fig 7B) . These results suggested that the inhibitory effect of EIPA on cell entry of LCMV was highly unlikely due to a blockade of PS-mediated cell entry.
Effect of zoniporide on LCMV multiplication. Zoniporide is a specific inhibitor for
NHE1 and has been used in clinical trials for the treatment of ischemia (19). We investigated the possibility of a repurposing of zoniporide as an anti-arenaviral drug. To test this possibility we examined the effect of zoniporide on LCMV infection in BHK-21 cells. Zoniporide inhibited multiplication of both ARM and Cl-13 strains of LCMV (Fig 8A) within a range of concentrations that did not have significant effects on cell viability (Fig   8C) . Consistent with an effect on cell entry mediated by LCMV GP, infection of rVSV/Cl-13GPC, but no of rVSV-WT, was affected by zoniporide treatment (Fig 8B) . Our results showed that EIPA inhibited very robustly multiplication of rARM/LASVGPC and rARM/JUNVGPC in BHK-21 cells (Fig 3A) , suggesting that inhibition of NHE function may interfere, at least in certain cell types, with cell entry mediated by GPs of HF arenaviruses. However, we cannot rule out the possibility that rLCMV where its GPC was replaced by GPC of LASV or JUNV, may not accurately recreate all the aspects of cell entry associated with infection by bona fide LASV or JUNV. Nevertheless, our findings suggested that inhibitors of NHE function may have potential value as anti-arenaviral drugs.
Reduced oxygen supply during ischemia results in increased glycolysis and consequent reduced intracellular pH that activates NHEs. Increased NHE directed intracellular Na + activates the sodium calcium exchanger, which results in an accumulation of intracellular Ca
2+
, leading to activation of cellular proteases, cardiomyocyte contracture, arrhythmias, and cell death (1). Accordingly, several NHE inhibitors are being investigated as potential therapeutic drugs to treat ischemia (19). We therefore explored the repurposing of NHE inhibitors as potential anti-arenaviral drugs.
There are nine different NHE isoforms. NHE3 is highly expressed in epithelial cells and was the one identified in the siRNA screen as required for efficient LCMV multiplication in HeLa cells (59) . EIPA inhibits to different degrees most NHE isoforms, whereas zoniporide is a rather specific inhibitor of NHE1. We found that similarly to EIPA, 
